Literature DB >> 27876157

Addressing Cognitive Deficits in Schizophrenia: Toward a Neurobiologically Informed Approach.

Ashley E Walker1, Jerrod D Spring2, Michael J Travis3.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 27876157      PMCID： PMC5371427          DOI： 10.1016/j.biopsych.2016.10.023

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN： 0006-3223            Impact factor:   13.382


× No keyword cloud information.
  9 in total

Review 1.  Assessing cognitive impairment in patients with schizophrenia.

Authors:  S Charles Schulz; Aimee Murray
Journal:  J Clin Psychiatry       Date:  2016-02       Impact factor: 4.384

Review 2.  Impact of cognitive and social cognitive impairment on functional outcomes in patients with schizophrenia.

Authors:  Michael F Green
Journal:  J Clin Psychiatry       Date:  2016-02       Impact factor: 4.384

Review 3.  Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans.

Authors:  Bita Moghaddam; John H Krystal
Journal:  Schizophr Bull       Date:  2012-08-16       Impact factor: 9.306

Review 4.  Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models.

Authors:  Joshua T Kantrowitz; Daniel C Javitt
Journal:  Clin Schizophr Relat Psychoses       Date:  2010-10

5.  Synaptic Plasticity: The Role of Learning and Unlearning in Addiction and Beyond.

Authors:  Alejandro Ramirez; Melissa R Arbuckle
Journal:  Biol Psychiatry       Date:  2016-09-08       Impact factor: 13.382

Review 6.  Layer 3 Excitatory and Inhibitory Circuitry in the Prefrontal Cortex: Developmental Trajectories and Alterations in Schizophrenia.

Authors:  Gil D Hoftman; Dibyadeep Datta; David A Lewis
Journal:  Biol Psychiatry       Date:  2016-06-04       Impact factor: 13.382

Review 7.  Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia.

Authors:  Amy F T Arnsten; Ragy R Girgis; David L Gray; Richard B Mailman
Journal:  Biol Psychiatry       Date:  2016-01-18       Impact factor: 13.382

Review 8.  Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia.

Authors:  Douglas L Boggs; Jon Carlson; Jose Cortes-Briones; John H Krystal; D Cyril D'Souza
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 9.  Global economic burden of schizophrenia: a systematic review.

Authors:  Huey Yi Chong; Siew Li Teoh; David Bin-Chia Wu; Surachai Kotirum; Chiun-Fang Chiou; Nathorn Chaiyakunapruk
Journal:  Neuropsychiatr Dis Treat       Date:  2016-02-16       Impact factor: 2.570
  9 in total
  5 in total

Review 1.  The Development of the Mesoprefrontal Dopaminergic System in Health and Disease.

Authors:  K Ushna S Islam; Norisa Meli; Sandra Blaess
Journal:  Front Neural Circuits       Date:  2021-10-12       Impact factor: 3.492

2.  Domains of Vulnerability, Resilience, Health Habits, and Mental and Physical Health for Health Disparities Research.

Authors:  Rebecca M Wolfe; Katie Beck-Felts; Brianna Speakar; William D Spaulding
Journal:  Behav Sci (Basel)       Date:  2022-07-18

Review 3.  A systematic review and narrative synthesis of data-driven studies in schizophrenia symptoms and cognitive deficits.

Authors:  Tesfa Dejenie Habtewold; Lyan H Rodijk; Edith J Liemburg; Grigory Sidorenkov; H Marike Boezen; Richard Bruggeman; Behrooz Z Alizadeh
Journal:  Transl Psychiatry       Date:  2020-07-21       Impact factor: 6.222

4.  Long-term cognitive trajectories and heterogeneity in patients with schizophrenia and their unaffected siblings.

Authors:  Md A Islam; T D Habtewold; F D van Es; P J Quee; E R van den Heuvel; B Z Alizadeh; R Bruggeman
Journal:  Acta Psychiatr Scand       Date:  2018-09-21       Impact factor: 6.392

5.  Metacognitive preserved generation strategy benefits for both younger and elderly participants with schizophrenia.

Authors:  Marie Izaute; Flavien Thuaire; Alain Méot; Fabien Rondepierre; Isabelle Jalenques
Journal:  PLoS One       Date:  2020-11-20       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.